A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies

Key Inclusion Criteria: * Diagnosis of non-myeloid malignancy, by histological or cytological confirmation. * Anemia related to myelosuppressive chemotherapy, defined as Hb ≤100 g/L at screening with documented participant's Hb level decrease ≥10 g/L after the initiation of chemotherapy as judged by the investigator. * Planned concurrent treatment of cancer (myelosuppressive chemotherapy) for at least 8 additional weeks. * Body weight ≥40 kg. * Eastern Cooperative Oncology Group (ECOG) performance status of 1 or 2. * Ferritin ≥50 nanograms (ng)/milliliter (mL) and transferrin saturation (TSAT) ≥10%. Key Exclusion Criteria: * Participants with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure. * Participants who are only receiving hormonal products, biological products, novel immunosuppressive products (such as programmed cell death protein-1 \[PD-1\] and programmed death-ligand 1 \[PD-L1\] checkpoint inhibitors) or targeted biological or radiation therapy to treat/manage their cancer, however if chemotherapy is co-administered with these products, then it is acceptable to enroll the participant. * Participants with hematocrit (HCT) ≥36%. * Participants who have received an RBC transfusion or ESA within 4 weeks of randomization. * Thromboembolic event (including but not limited to deep vein thrombosis \[DVT\], pulmonary embolism, myocardial infarction, stroke, transient ischemic attack \[TIA\] within previous 6 months of screening. * Clinic…